Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 |
| Expenses | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 |
| Operating Profit | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 |
| OPM % | 9% | -76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% |
| Other Income | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 |
| Interest | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 |
| Depreciation | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 |
| Profit before tax | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| Tax % | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| EPS in Rs | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.38 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,431 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,240 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 192 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% | 13% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 | 2 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 92 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 103 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 | -2 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | 0% | |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | -2 |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | -2.05 | -1.58 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | -3% | -2% | 15% | ||
| Compounded Profit Growth | % | % | 25% | -83% | ||
| Stock Price CAGR | % | -13% | 32% | 21% | ||
| Return on Equity | % | -7% | -12% | 0% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 |
| Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 |
| Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 |
| Cash from Investing Activity | -85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | -99 |
| Cash from Financing Activity | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 |
| Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | -0 | -4 | 1 |
| Free Cash Flow | 14 | 108 | -25 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO/OP | 92% | 85% | 103% | 49% | -277% | 106% | -113% | 104% | 83% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 144 | 146 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 134 | 140 |
| Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 | -24 |
| ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% | 5% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 37.19% | 30.49% | 30.49% | 37.27% | 37.27% | 37.23% | 37.94% | 42.01% | 42.01% | 42.00% | 42.00% | 41.93% |
| FIIs | 17.86% | 16.62% | 15.80% | 14.00% | 14.25% | 14.67% | 14.63% | 14.25% | 13.58% | 11.98% | 11.59% | 11.52% |
| DIIs | 1.79% | 1.75% | 2.97% | 2.83% | 3.37% | 3.19% | 2.61% | 2.62% | 2.69% | 3.64% | 3.75% | 3.74% |
| Public | 43.16% | 51.14% | 50.73% | 45.89% | 45.11% | 44.92% | 44.82% | 41.10% | 41.71% | 42.37% | 42.66% | 42.79% |
| No. of Shareholders | 74,473 | 72,918 | 73,912 | 77,170 | 71,882 | 83,148 | 75,791 | 74,334 | 72,479 | 71,890 | 70,400 | 70,490 |
Fundamentals
Market Cap₹ 3,635 Cr.
Current Price₹ 750
Stock P/E851
Book Value₹ 346
ROCE4.86 %
ROE-0.13 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)15%
Compounded Profit Growth (TTM)-83%
Consolidated figures.
Valuation
Market capRs 3,435 Cr
Enterprise valueRs 4,227 Cr
Price to book3.14x
Price to sales2.40x
EV / EBITDA21.82x
EV / EBIT46.52x
EV / sales2.95x
Price to cash flow16.14x
Earnings yield-0.05%
P/E, 3-year average4566.82x
P/B, 3-year average1.43x
P/E, 5-year average2293.83x
P/B, 5-year average1.73x
Profitability
Operating margin (excl. other income)16.07%
Operating margin (incl. other income)16.72%
EBITDA margin13.53%
Pre-tax margin-0.11%
Net profit margin-0.11%
Net margin, latest quarter4.27%
ROE0.05%
ROCE6.01%
ROA0.02%
ROE, 3-year average-16.01%
ROCE, 3-year average-3.13%
ROA, 3-year average-7.45%
ROE, 5-year average-7.04%
ROCE, 5-year average1.03%
ROA, 5-year average-3.03%
ROIC (approx.)4.82%
Other income / net worth0.76%
Growth
Sales growth (latest year)-0.40%
Sales CAGR, 3 years0.40%
Sales CAGR, 5 years-0.58%
Profit CAGR, 5 years-65.75%
Sales growth QoQ-1.47%
Profit growth QoQ69.90%
Sales growth YoY (latest quarter)19.57%
Profit growth YoY (latest quarter)55.04%
Per share
EPS (TTM)Rs -0.34
EPS (latest year)Rs 0.11
EPS (latest quarter)Rs 3.39
EPS, 3-year averageRs -54.56
EPS, 5-year averageRs -23.64
Book value per shareRs 227.72
Sales per shareRs 297.89
Cash flow per shareRs 44.29
Free cash flow per shareRs 21.02
Dividend per share, 3-year averageRs 3.00
Dividend per share, 5-year averageRs 5.00
Dividends
Dividend payout, 5-year average11.36%
Efficiency
Asset turnover0.58x
Fixed asset turnover1.08x
Inventory turnover2.48x
Inventory days147 days
Debtor days93 days
Debtors turnover3.93x
Creditor days146 days
Cash conversion cycle140 days
Working capital days-24 days
Leverage
Total debtRs 796 Cr
Cash and bankRs 4 Cr
Net debtRs 792 Cr
Debt to equity0.73x
Net debt / EBITDA4.09x
Interest coverage0.98x
Current ratio (filing 2026-03-31)0.96x
Quick ratio (filing 2026-03-31)0.60x
Trade payables (filing 2026-03-31)Rs 274 Cr
Owners' fund to total sources49.03%
Debt to assets35.67%
Cash flow
Cash from Operating Activity (latest year)Rs 213 Cr
Cash from Investing Activity (latest year)Rs -37 Cr
Cash from Financing Activity (latest year)Rs -180 Cr
Net Cash Flow (latest year)Rs -4 Cr
Free cash flow (latest year)Rs 101 Cr
FCFE (approx.: FCF + change in debt)Rs -114 Cr
Sales to cash flow6.03x
Statement figures
Net sales (TTM)Rs 1,431 Cr
Net sales (latest year)Rs 1,284 Cr
Sales (latest quarter)Rs 382 Cr
Operating profit excl. other income (latest year)Rs 206 Cr
Operating profit (latest quarter)Rs 62 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 194 Cr
PBDT (TTM)Rs 101 Cr
Profit before tax (TTM)Rs -2 Cr
Net profit (TTM)Rs -2 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 16 Cr
Depreciation (TTM)Rs 103 Cr
Depreciation (latest quarter)Rs 27 Cr
Interest (TTM)Rs 92 Cr
Cost of goods sold (latest year)Rs 789 Cr
Total expenditure (latest year)Rs 1,077 Cr
Total income (latest year)Rs 1,292 Cr
Share capitalRs 40 Cr
ReservesRs 1,054 Cr
Shareholders' fundsRs 1,094 Cr
Total assetsRs 2,232 Cr
Net blockRs 1,193 Cr
Capital work in progressRs 280 Cr
InvestmentsRs 2 Cr
ReceivablesRs 327 Cr
InventoryRs 318 Cr
Other liabilitiesRs 342 Cr
Shares outstanding (crore)4.81
Ownership
Promoter holding41.93% (-0.08 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 3.14 is at the 69th percentile (median 2.65).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | SOLARA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -1.7% | -2.8% | +1.1 pts |
| 1 month | +11.1% | -6.8% | +17.9 pts |
| 3 months | +24.1% | -7.6% | +31.8 pts |
| 6 months | +68.0% | +0.4% | +67.6 pts |
| 1 year | +6.3% | -9.9% | +16.2 pts |
| 2 years | -8.6% | -13.6% | +5.0 pts |
| 3 years | +100.2% | +14.2% | +86.0 pts |
| 5 years | -55.6% | +27.9% | -83.5 pts |
3 mutual fund schemes hold about ₹27 Cr.
Over three months 0 bought more and 3 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Aditya Birla SL Flexi Cap Fund | 0.09% | 27 | -19% |
| Bandhan BSE Healthcare Index Fund | 0.09% | 0 | -16% |
| Motilal Oswal BSE 1000 Index Fund | 0.01% | 0 | -19% |
Red flags
F-score 8 of 8| explain | Low interest cover Interest cover 1.0x in 2026 |
| look | Profit leans on other income Other income was 1541% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹382 Cr +19.7% vs Jun 2025.
Net profit ₹16 Cr +45.5%.
Against our estimate for Jun 2026: sales -7.2%, profit +1394.0% in line. Our estimate for Sep 2026: sales Rs 411 Cr, profit Rs -1 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-09-17 | Annual General Meeting | |
| 2024-05-15 | Rights 1:3 @ Premium Rs 365/- | |
| 2023-09-08 | Annual General Meeting | |
| 2022-08-12 | Annual General Meeting | |
| 2021-08-18 | Annual General Meeting/Dividend - Rs 3 Per Share | |
| 2020-11-19 | Interim Dividend - Rs 4 Per Share | |
| 2020-07-28 | Annual General Meeting/Dividend - Rs 2 Per Share | |
| 2019-08-06 | Annual General Meeting/Dividend - Rs 5 Per Share | |
| 2018-09-18 | Annual General Meeting |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)
Quick answers
What is the market cap of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd (SOLARA) has a market capitalisation of Rs 3,635 Cr. at the 2026-10-01 close.
What is the P/E ratio of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd trades at a P/E of 851 on trailing twelve-month profit, at the 2026-10-01 close.
What were Solara Active Pharma Sciences Ltd's latest quarterly results?
In the Jun 2026 quarter, Solara Active Pharma Sciences Ltd sales was Rs 382 Cr (+19.7% vs Jun 2025) and net profit was Rs 16 Cr.
What is the 52-week high and low of Solara Active Pharma Sciences Ltd?
The 52-week high is Rs 774.00 and the 52-week low is Rs 422.00.